Breaking News Instant updates and real-time market news.

AVEO

Aveo Pharmaceuticals

$2.97

-0.32 (-9.73%)

, S

Sprint

$6.55

0.01 (0.15%)

07:30
10/02/18
10/02
07:30
10/02/18
07:30

Unusual put flow in option market yesterday

Notable put activity was cited Monday in AVEO Oncology (AVEO), Sprint (S), Williams Sonoma (WSM), 3D Systems (DDD), Infinera (INFN), and Imperva (IMPV).

AVEO

Aveo Pharmaceuticals

$2.97

-0.32 (-9.73%)

S

Sprint

$6.55

0.01 (0.15%)

WSM

Williams-Sonoma

$65.01

-0.695 (-1.06%)

DDD

3D Systems

$18.06

-0.83 (-4.39%)

INFN

Infinera

$6.17

-1.125 (-15.42%)

IMPV

Imperva

$45.21

-1.14 (-2.46%)

  • 02

    Oct

  • 02

    Oct

  • 02

    Oct

  • 03

    Oct

  • 04

    Oct

  • 05

    Oct

  • 11

    Oct

  • 17

    Oct

  • 19

    Oct

  • 06

    Nov

  • 12

    Nov

  • 13

    Nov

  • 27

    Nov

AVEO Aveo Pharmaceuticals
$2.97

-0.32 (-9.73%)

07/19/18
PIPR
07/19/18
NO CHANGE
Target $5
PIPR
Overweight
Aveo Pharmaceuticals selloff a buying opportunity, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff recommends using the 32% selloff this week in shares of Aveo Pharmaceuticals as a buying opportunity. He reiterates an Overweight rating on the name with a $5 price target. The analyst views the pullback on news of data from the Phase III Tivo-3 trial of tivozanib in third-line renal cell carcinoma coming in Q4 as an overreaction. Tenthoff continues to believe Tivo-3 will be positive based on prior Tivo-1 progression-free survival benefit versus historical sorafenib. With positive Tivo-3 data, Aveo could respond to the 2013 tivozanib complete response letter with potential FDA approval next year, Tenthoff tells investors in a research note.
08/16/18
HCWC
08/16/18
INITIATION
Target $6.5
HCWC
Buy
Aveo Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated Aveo Pharmaceuticals (AVEO) with a Buy rating and $6.50 price target, citing the view that tivozanib offers potentially the "best-in-class" safety profile when compared to leading TKIs on the market, such as Pfizer's (PFE) Sutent and Bayer's (BAYRY) Nexavar. Ramakanth projects tivozanib to reach the U.S. market in 2020 and achieve risk-adjusted revenues of $651M by 2030.
08/16/18
08/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Post Holdings (POST) initiated with an Overweight at Piper Jaffray. 2. Stryker (SYK) initiated with a Buy at BTIG. 3. Aveo Pharmaceuticals (AVEO) initiated with a Buy at H.C. Wainwright. 4. Uxin (UXIN) initiated with a Buy at Goldman Sachs. 5. AcelRx (ACRX) initiated with a Buy at Ladenburg. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/01/18
PIPR
10/01/18
NO CHANGE
Target $5
PIPR
Overweight
Piper remains confident in Aveo reporting positive TIVO-3 data
After an Independent Steering Committee recommended the initiation of top-line analysis of Aveo Pharmaceuticals' Phase 3 TIVO-3 trial of tivozanib in third-line renal cell carcinoma, Piper Jaffray analyst Edward Tenthoff noted that the lower than expected event rate of 242 events "minimally reduces" powering of the trial to 88% from the originally planned for 90%, but he remains confident in positive top-line TIVO-3 data being reported in about 6 weeks. Tenthoff reiterates his Overweight rating and $5 price target on Aveo shares.
S Sprint
$6.55

0.01 (0.15%)

09/25/18
OPCO
09/25/18
NO CHANGE
Target $24
OPCO
Outperform
CenturyLink CFO departure raises concerns, says Oppenheimer
Oppenheimer analyst Timothy Horan notes CenturyLink (CTL) has announced that CFO Sunit Patel will depart as of September 28th to join T-Mobile (TMUS) to lead the Sprint (S)/T-Mobile merger and integration efforts. The analyst expects weakness in CenturyLink's stock, as investors will likely be concerned with synergy realization after Patel's departure. While Horan says his departure is disappointing, he believes CenturyLink has a deep management bench, and Jeff Storey, CEO, will continue to be the driving force behind restructuring and expense reductions at the company. He reiterates an Outperform rating and $24 price target on the shares.
08/07/18
SBSH
08/07/18
NO CHANGE
SBSH
Citi credit sees 80% chance of T-Mobile, Sprint merger approval
Citi credit analyst David Phipps believes T-Mobile (TMUS) and Sprint (S) have an 80% chance of winning approval for their proposed merger. The market regularly puts merger approval odds at 50/50, Phipps tells investors in a fixed income research note. The analyst remains bullish on Sprint credit.
06/28/18
06/28/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Air Transport Services (ATSG) upgraded to Buy from Hold at Stifel with analyst David Ross saying shares are attractive at current levels given long-term growth prospects. 2. T-Mobile (TMUS) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche stating that recent conversations with some of his DC contacts have made him more optimistic that a deal to merge with Sprint (S) could be approved. 3. Talend (TLND) upgraded to Buy from Neutral at with analyst Tyler Radke saying a survey of Chief Data Officers shows "strong spending signals" while the company's competitive backdrop is favorable amid "increasing cloud tailwinds". 4. Regions Financial (RF) upgraded to Neutral from Underperform at Baird with analyst David George citing the recent pullback, which he thinks has made the valuation more reasonable. 5. Twilio (TWLO) upgraded to Buy from Hold at Argus with analyst Jim Kelleher saying the pullback in the stock price has created a more favorable entry point. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/18
RILY
09/13/18
INITIATION
Target $46
RILY
Buy
Shenandoah initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Zack Silver started Shenandoah Telecommunications (SHEN) with a Buy rating and $46 price target. The analyst sees the company benefiting from the merger between Sprint (S) and T-Mobile (TMUS).
WSM Williams-Sonoma
$65.01

-0.695 (-1.06%)

08/29/18
LOOP
08/29/18
NO CHANGE
Target $175
LOOP
Buy
RH Q2 may outperform after strong Williams-Sonoma results, says Loop Capital
Loop Capital analyst Anthony Chukumba kept his Buy rating and $175 price target on RH (RH) ahead of its Q2 earnings next week, saying the better than expected results in the quarter from Williams-Sonoma (WSM) is a positive harbinger for the company. The analyst expects investors to focus on RH's "comparable brand revenue growth, Q3 guidance, recent senior executive departures, and early results from the recently opened next-generation design galleries".
08/27/18
ARGS
08/27/18
NO CHANGE
Target $80
ARGS
Buy
Williams-Sonoma price target raised to $80 from $67 at Argus
Argus analyst Chris Graja raised his price target on Williams-Sonoma to $80 and kept his Buy rating after its Q2 earnings beat. The analyst notes that the company's West Elm segment continued to make "a strong connection with millennial-generation shoppers", growing sales 9.5% after a 10.1% growth in last year's Q2 while also making inroads in its social media presence. Graja is also positive on Williams-Sonoma's valuation, saying the 14-times forward EBIT multiple for the next 12 months - which would still be below the peers' 14.6-times in the home products retail business - would value the shares around $82 in one year. The analyst is still concerned over the near term headwinds on the stock from any potential impact of U.S.-China trade tariffs.
08/23/18
FBCO
08/23/18
NO CHANGE
Target $55
FBCO
Underperform
Williams-Sonoma price target raised to $55 from $48 at Credit Suisse
Credit Suisse analyst Seth Sigman raised his price target for Williams-Sonoma to $55 from $48 saying headline adjusted results were better, with a 9c EPS beat, healthy comps, and higher gross margin, which he expects to send the stock up initially. However, the analyst notes that retail comps included a 40 bps benefit from accelerated revenue recognition, and profitability does not appear to be as strong on an apples-to-apples basis. He reiterates an Underperform rating on the shares.
08/23/18
RBCM
08/23/18
NO CHANGE
Target $67
RBCM
Sector Perform
Williams-Sonoma price target raised to $67 from $61 at RBC Capital
RBC Capital analyst Scot Ciccarelli raised his price target on Williams-Sonoma to $67 after its "solid" Q2 marked a beat for the second consecutive quarter. The analyst notes that the gross margins were particularly encouraging, but he remains concerned about its longer-term margin structure. Ciccarelli also keeps his Sector Perform rating on Williams-Sonoma in spite of its modest valuation, stating that margins will remain under pressure because of the competition around pricing and free shipping.
DDD 3D Systems
$18.06

-0.83 (-4.39%)

07/26/18
07/26/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. PIPER CUTS 3D SYSTEMS TO UNDERWEIGHT: Piper Jaffray analyst Troy Jensen downgraded 3D Systems (DDD) to Underweight from Neutral with a $10 price target. He believes competition for the company's main product lines is intensifying. The analyst also thinks 3D will need to increase spending on direct sales, customer support and consulting, meaning "meaningful profitability" will likely be more challenged than revenue growth throughout 2018. He views the stock as overvalued. While Jensen continues to believe the overall 3D printing industry is "growing rapidly," he remains cautious on shares of 3D Systems and Stratasys (SSYS). He reiterated a Neutral rating on the latter. OPCO CUTS E.L.F. TO PERFORM: Oppenheimer analyst Rupesh Parikh downgraded e.l.f. Beauty (ELF) to Perform from Outperform saying the bull case is more uncertain from here. The analyst does not have a price target for the shares. Recent developments, including "still challenging trends" in the mass category and increased tariff uncertainty, bring greater risk to consensus forecasts, Parikh tells investors in a research note. He is harder-pressed to see the case for share outperformance. Ulta Beauty (ULTA) and Estee Lauder (EL) remain Parikh's top picks in beauty. FACEBOOK GETS MULTIPLE DOWNGRADES AFTER Q2 EARNINGS: Nomura Instinet analyst Mark Kelley downgraded Facebook (FB) to Neutral from Buy after the company delivered "underwhelming" Q2 results and guided for revenue growth deceleration through the end of the year. The revenue guidance paired with the expectation for mid-30% operating margins in the medium term or possibly longer means consensus numbers will be cut "drastically," he said. He lowered his price target on Facebook shares to $183 from $228. Facebook was also downgraded to Neutral from Buy by UBS analyst Eric Sheridan, who also lowered his price target for the shares to $180 from $212, and to Outperform from Strong Buy at Raymond James. Facebook shares are down over 19% in late morning trading. PIPER SAYS BIOGEN SELLOFF A BUYING OPPORTUNITY: Biogen (BIIB) shares "will recover and continue to work" into aducanumab's full Phase 3 data in 2020, Piper Jaffray analyst Christopher Raymond told investors. With the stock having run up into these data, the analyst said he understood the "sell-the-news" phenomenon. He believes, however, that the fundamental concerns he's heard from investors "don't seem to hold water." The analyst said to buy Biogen shares on the selloff. He kept an Overweight rating on the name with a $400 price target.
07/30/18
JPMS
07/30/18
NO CHANGE
Target $9.5
JPMS
Underweight
JPMorgan cautious on 3D printing names into Q2 results
JPMorgan analyst Paul Coster is cautious heading into the Q2 results for 3D printing pure-plays, 3D Systems (DDD) and Stratasys (SSYS). The analyst sees "intense" competition in every segment, and continued commoditization of the entry-level market segment. He has an Underweight rating on 3D with a $9.50 price target and Underweight rating on Stratasys with a $17 price target.
08/08/18
PIPR
08/08/18
NO CHANGE
Target $14
PIPR
Underweight
3D Systems price target raised to $14 from $10 at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target for 3D Systems to $14 saying the company reported "solid" Q2 results with revenue and earnings upside. Printer sales drove the revenue beat with sales growing 41% year-over-year despite only a modest contribution from the company's new printer portfolio, Jensen tells investors in a post-earnings research note. The analyst, however, believes 3D's operating expenses will continue to increase to fend off competition and launch its new line-up of printers. He reiterates an Underweight rating on the shares.
08/08/18
LOOP
08/08/18
NO CHANGE
Target $17
LOOP
Hold
3D Systems price target raised to $17 from $13 at Loop Capital
Loop Capital analyst Ananda Baruah raised his price target on 3D Systems to $17 after its Q2 results, noting the company reported a third consecutive quarter of "very solid" performance. The analyst states that 3D Systems is making "foundational" strides in positioning to generate revenue growth while broadening the use of 3D printing in the production market. Baruah also kept his Hold rating, saying that at 49-times forward earnings valuation multiple, the stock is "volatile and noisy while the business model normalizes".
INFN Infinera
$6.17

-1.125 (-15.42%)

09/25/18
MSCO
09/25/18
INITIATION
Target $9.5
MSCO
Overweight
Infinera reinstated with an Overweight at Morgan Stanley
Morgan Stanley analyst Meta Marshall reinstated coverage of Infinera with an Overweight rating and $9.50 price target, placing it at the top of her Optical Scorecard as she believe the company's Coriant acquisition could help it generate upwards of $2 of long term earnings power if it is successful. Access to Coriant's Tier 1 customers can help Infinera's revenues and greater leverage of their fab and vertical integration can help its profits, Marshall tells investors.
10/01/18
MKMP
10/01/18
DOWNGRADE
MKMP
Sell
Infinera downgraded to Sell from Neutral at MKM Partners
10/01/18
MKMP
10/01/18
DOWNGRADE
Target $5.5
MKMP
Sell
Infinera downgraded to Sell at MKM Partners on CenturyLink client loss
As reported earlier, MKM Partners analyst Michael Genovese downgraded Infinera (INFN) to Sell from Neutral and lowered his price target to $5.50 from $10. The analyst says that his checks suggest the company's loss of its biggest customer CenturyLink (CTL) to Ciena (CIEN) amid concerns with its ability to produce "new leading edge digital signal processors every 18-30 months". Genovese expects Infinera's upcoming guidance for Q4 and FY19 to be disappointing on revenues and margins, while his price target that assumes a valuation multiple of 0.8-times enterprise value to expected FY19 sales "reflects increasing concerns about the long-term competitiveness of the company".
10/01/18
10/01/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. OPCO CUTS CHIPOTLE TO UNDERPERFORM: Oppenheimer analyst Brian Bittner downgraded Chipotle Mexican Grill (CMG) to Underperform from Perform with a $400 price target. Since its new CEO announcement in February, Chipotle is up 82% and has been upgraded 10 different times by the Street, Bittner noted. The company's "high-flying" valuation has "priced in" persistent mid-single same-store-sales and a path to at least $20 of earnings per share versus $8-$9 this year, the analyst added. His work suggests this earnings path is too optimistic, even when assuming "healthy sales." INTEL CUT TO UNDERWEIGHT BY BARCLAYS: Barclays analyst Blayne Curtis downgraded Intel (INTC) to Underweight from Equal Weight and lowered his price target for the shares to $38 from $53. End-market tailwinds that propelled the run in shares, namely PC shortages and the slowing of server growth, are likely to reverse, Curtis believes. Further, the analyst expects Intel will see increased competition from AMD (AMD) and declining free cash flow returns. In addition, the names that have been floated in the CEO search "have yet to yield any disruptive potential candidates to take on all of these challenges," Curtis said. By squandering its manufacturing lead, the company now faces a "costly battle to retain share amidst a near-term slowing of its end markets," concluded the analyst. MKM CUTS INFINERA TO SELL: MKM Partners analyst Michael Genovese downgraded Infinera (INFN) to Sell from Neutral and lowered his price target to $5.50 from $10. The analyst said his checks suggest the company's loss of its biggest customer CenturyLink (CTL) to Ciena (CIEN) amid concerns with its ability to produce "new leading edge digital signal processors every 18-30 months". Genovese expects Infinera's upcoming guidance for Q4 and FY19 to be disappointing on revenues and margins, while his price target that assumes a valuation multiple of 0.8-times enterprise value to expected FY19 sales "reflects increasing concerns about the long-term competitiveness of the company." TEVA UPGRADED AT LEERINK, GOLDMAN: Leerink analyst Ami Fadia upgraded Teva (TEVA) to Market Perform from Underperform due to improving business fundamentals as well as the improving multiples for the overall generics sector. The analyst, who believes the company's fundamentals have improved meaningfully and put Teva in a position to pay down $3.5B in debt by YE18, raised his price target on the shares to $24 from $16. Meanwhile, Goldman Sachs analyst Jami Rubin added Teva to Goldman's Conviction List with a Buy rating, calling the recent selloff in the shares a "head scratcher." Recent concerns raised in the marketplace regarding second half of 2018 headwinds and Eli Lilly's (LLY) galcenuzemab approval were already expected and well understood, Rubin tells investors in a research note. DEUTSCHE CUTS LAM RESEARCH, APPLIED MATERIALS TO HOLD: Deutsche Bank analyst Sidney Ho downgraded Lam Research (LRCX) to Hold and lowered his price target for the shares to $170 from $230, and downgraded Applied Materials (AMAT) to Hold and lowered his price target for the shares to $43 from $58. Semicap Equipment stocks are not expensive but lack positive catalysts, Ho said. The analyst believes investor fears over that the industry has reached a cyclical peak will remain as long as the memory market stays weak. Further, he sees risk is for additional capex push-outs, especially in the first half of 2019.
IMPV Imperva
$45.21

-1.14 (-2.46%)

07/27/18
MONN
07/27/18
DOWNGRADE
MONN
Neutral
Imperva downgraded to Neutral from Buy at Monness Crespi
07/27/18
DADA
07/27/18
DOWNGRADE
Target $46
DADA
Neutral
Imperva downgraded to Neutral at DA Davidson on subscription revenue transition
As reported earlier, DA Davidson analyst Mark Kelleher downgraded Imperva to Neutral from Buy and lowered his price target to $46 from $56. The analyst notes that while the company's focus on the security market and the DDoS opportunity is a positive, the faster than anticipated transition to subscription revenue model is weighing on top-line growth. Kelleher adds that earnings are also constrained by Imperva's acquisition costs, forecasting 2019 as a transition year when the company can work to improve its salesforce productivity.
07/27/18
OPCO
07/27/18
DOWNGRADE
OPCO
Perform
Imperva downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Shaul Eyal downgraded Imperva to Perform from Outperform after the company reported "disappointing" Q2 results. In a research note to investors, Eyal says he is moving to the sidelines, as Imperva needs more time to complete its model transition and U.S. restructuring initiatives. The analyst says that while yesterday's after-hours shares' move could be perceived as an attractive valuation level, he would stay away for now.
07/27/18
DADA
07/27/18
DOWNGRADE
DADA
Neutral
Imperva downgraded to Neutral from Buy at DA Davidson

TODAY'S FREE FLY STORIES

NKE

Nike

$83.97

-0.87 (-1.03%)

10:40
02/21/19
02/21
10:40
02/21/19
10:40
On The Fly
Analyst sees 'minimal' lasting damage to Nike brand after Duke star's shoe splits »

Shares of Nike (NKE)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFT

Weatherford

$0.79

-0.0263 (-3.21%)

10:40
02/21/19
02/21
10:40
02/21/19
10:40
Options
10.1K Weatherford Mar 1 calls trade as shares drop 2c to 80c »

10.1K Weatherford Mar 1…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

10:40
02/21/19
02/21
10:40
02/21/19
10:40
General news
Treasury Action: yields have cheapened despite some disappointing data »

Treasury Action: yields…

KAR

KAR Auction

$48.30

1.56 (3.34%)

10:37
02/21/19
02/21
10:37
02/21/19
10:37
Upgrade
KAR Auction rating change  »

KAR Auction upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 07

    Mar

  • 13

    Mar

  • 14

    Mar

NCLH

Norwegian Cruise Line

$55.71

1.99 (3.70%)

10:32
02/21/19
02/21
10:32
02/21/19
10:32
Recommendations
Norwegian Cruise Line analyst commentary  »

Buckingham says backdrop…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 03

    Mar

  • 28

    May

BSX

Boston Scientific

$40.03

-0.1 (-0.25%)

10:30
02/21/19
02/21
10:30
02/21/19
10:30
Options
Bullish option flow in Boston Scientific »

Bullish option flow in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 27

    Feb

  • 06

    Mar

  • 18

    May

  • 28

    May

SNPS

Synopsys

$100.68

-2.3 (-2.23%)

10:26
02/21/19
02/21
10:26
02/21/19
10:26
Recommendations
Synopsys analyst commentary  »

Synopsys weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Feb

  • 25

    Feb

  • 25

    Feb

  • 26

    Feb

  • 26

    Feb

  • 03

    Mar

  • 08

    Mar

  • 14

    Mar

  • 17

    Mar

  • 16

    Jul

  • 17

    Jul

  • 26

    Sep

  • 27

    Sep

NWL

Newell Brands

$17.18

0.05 (0.29%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Periodicals
Newell Brands CEO faces board pressure following poor sales, WSJ reports »

Newell Brands CEO Michael…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley consumer goods analysts to hold analyst/industry conference call »

Executive Director of…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

, ESALY

Eisai

$0.00

(0.00%)

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan large-cap biotech analysts to hold an analyst/industry conference call »

Large Cap Biotech Analyst…

BIIB

Biogen

$323.78

-11.23 (-3.35%)

ESALY

Eisai

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 28

    May

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
JPMorgan retail analysts to hold an analyst/industry conference call »

Retail Analysts Boss and…

10:25
02/21/19
02/21
10:25
02/21/19
10:25
Conference/Events
Morgan Stanley sports/footwear analyst to hold analyst/industry conference call »

Sports & Footwear…

EEM

iShares MSCI Emerging Markets ETF

$42.48

-0.175 (-0.41%)

10:20
02/21/19
02/21
10:20
02/21/19
10:20
Options
Size three-way spread in iShares Emerging Markets Fund as shares tick lower »

Size three-way spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
02/21/19
02/21
10:17
02/21/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
02/21/19
02/21
10:16
02/21/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
U.S. leading index dipped 0.1% to 111.3 in January »

U.S. leading index dipped…

10:15
02/21/19
02/21
10:15
02/21/19
10:15
General news
Breaking General news story  »

Week of 2/15 EIA Natural…

HOME

At Home Group

$23.84

0.01 (0.04%)

, HLIT

Harmonic

$5.51

0.19 (3.57%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Initiation
Fly Intel: Top five analyst initiations »

Catch up on today's…

HOME

At Home Group

$23.84

0.01 (0.04%)

HLIT

Harmonic

$5.51

0.19 (3.57%)

ATKR

Atkore

$24.08

-0.09 (-0.37%)

BTX

BioTime

$1.24

0.08 (6.90%)

VRCA

Verrica Pharmaceuticals

$10.99

(0.00%)

APHA

Aphria

$10.40

0.24 (2.36%)

KSHB

KushCo Holdings

$0.00

(0.00%)

HEXO

HEXO Corp

$6.11

0.13 (2.17%)

CGC

Canopy Growth

$45.44

-0.74 (-1.60%)

ACB

Aurora Cannabis

$7.18

0.12 (1.70%)

TLRY

Tilray

$80.25

-0.82 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 26

    Feb

  • 01

    Mar

  • 07

    Mar

  • 18

    Mar

  • 18

    Mar

GRMN

Garmin

$82.02

-1 (-1.20%)

, BIIB

Biogen

$324.13

-10.88 (-3.25%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Downgrade
Fly Intel: Top five analyst downgrades »

Catch up on today's…

GRMN

Garmin

$82.02

-1 (-1.20%)

BIIB

Biogen

$324.13

-10.88 (-3.25%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

DHI

D.R. Horton

$39.91

0.04 (0.10%)

LEN

Lennar

$49.12

0.16 (0.33%)

GIS

General Mills

$46.68

-0.26 (-0.55%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

  • 25

    Feb

  • 25

    Feb

  • 28

    May

CAJ

Canon

$29.10

-0.02 (-0.07%)

, SAM

Boston Beer

$302.00

34.05 (12.71%)

10:11
02/21/19
02/21
10:11
02/21/19
10:11
Upgrade
Fly Intel: Top five analyst upgrades »

Catch up on today's…

CAJ

Canon

$29.10

-0.02 (-0.07%)

SAM

Boston Beer

$302.00

34.05 (12.71%)

X

U.S. Steel

$24.25

0.25 (1.04%)

FARO

Faro Technologies

$45.51

1.73 (3.95%)

AAN

Aaron's

$54.10

0.46 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KEM

Kemet

$18.86

-0.57 (-2.93%)

10:10
02/21/19
02/21
10:10
02/21/19
10:10
Options
Put buyers in Kemet Corp as shares slip »

Put buyers in Kemet Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
02/21/19
02/21
10:10
02/21/19
10:10
General news
U.S. existing home sales dropped 1.2% in January to 4.94 M »

U.S. existing home sales…

CPRX

Catalyst Pharmaceuticals

$2.80

0.04 (1.45%)

10:08
02/21/19
02/21
10:08
02/21/19
10:08
On The Fly
Catalyst Pharmaceuticals defends pricing for Firdapse after Sanders slams company »

Nearly three weeks after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
Leading Indicators data reported »

January Leading…

10:05
02/21/19
02/21
10:05
02/21/19
10:05
General news
FX Action: The dollar »

FX Action: The dollar was…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.